Switch theme
Sign up to access all valuation multiples
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
2010
21
LTM Revenue $42.0M
LTM EBITDA $9.2M
$60.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Synergy CHC has a last 12-month revenue (LTM) of $42.0M and a last 12-month EBITDA of $9.2M.
In the most recent fiscal year, Synergy CHC achieved revenue of $34.8M and an EBITDA of $6.5M.
Synergy CHC expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Synergy CHC valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $42.0M | XXX | $34.8M | XXX | XXX | XXX |
| Gross Profit | $28.6M | XXX | $23.6M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $9.2M | XXX | $6.5M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $8.1M | XXX | $5.8M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $3.3M | XXX | $2.1M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $26.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 1, 2025, Synergy CHC's stock price is $4.
Synergy CHC has current market cap of $32.2M, and EV of $60.1M.
See Synergy CHC trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.1M | $32.2M | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 1, 2025, Synergy CHC has market cap of $32.2M and EV of $60.1M.
Synergy CHC's trades at 1.7x EV/Revenue multiple, and 9.3x EV/EBITDA.
Equity research analysts estimate Synergy CHC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synergy CHC has a P/E ratio of 9.8x.
See valuation multiples for Synergy CHC and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32.2M | XXX | $32.2M | XXX | XXX | XXX |
| EV (current) | $60.1M | XXX | $60.1M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.5x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBIT | 7.4x | XXX | 10.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 9.8x | XXX | 15.1x | XXX | XXX | XXX |
| EV/FCF | -16.4x | XXX | -12.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynergy CHC's last 12 month revenue growth is 24%
Synergy CHC's revenue per employee in the last FY averaged $1.7M, while opex per employee averaged $0.8M for the same period.
Synergy CHC's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synergy CHC's rule of X is 82% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Synergy CHC and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 50% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synergy CHC acquired XXX companies to date.
Last acquisition by Synergy CHC was XXXXXXXX, XXXXX XXXXX XXXXXX . Synergy CHC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Synergy CHC founded? | Synergy CHC was founded in 2010. |
| Where is Synergy CHC headquartered? | Synergy CHC is headquartered in United States of America. |
| How many employees does Synergy CHC have? | As of today, Synergy CHC has 21 employees. |
| Who is the CEO of Synergy CHC? | Synergy CHC's CEO is Mr. Jack Ross. |
| Is Synergy CHC publicy listed? | Yes, Synergy CHC is a public company listed on NAS. |
| What is the stock symbol of Synergy CHC? | Synergy CHC trades under SNYR ticker. |
| When did Synergy CHC go public? | Synergy CHC went public in 2013. |
| Who are competitors of Synergy CHC? | Similar companies to Synergy CHC include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Synergy CHC? | Synergy CHC's current market cap is $32.2M |
| What is the current revenue of Synergy CHC? | Synergy CHC's last 12 months revenue is $42.0M. |
| What is the current revenue growth of Synergy CHC? | Synergy CHC revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Synergy CHC? | Current revenue multiple of Synergy CHC is 1.4x. |
| Is Synergy CHC profitable? | Yes, Synergy CHC is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synergy CHC? | Synergy CHC's last 12 months EBITDA is $9.2M. |
| What is Synergy CHC's EBITDA margin? | Synergy CHC's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Synergy CHC? | Current EBITDA multiple of Synergy CHC is 6.5x. |
| What is the current FCF of Synergy CHC? | Synergy CHC's last 12 months FCF is -$3.7M. |
| What is Synergy CHC's FCF margin? | Synergy CHC's last 12 months FCF margin is -9%. |
| What is the current EV/FCF multiple of Synergy CHC? | Current FCF multiple of Synergy CHC is -16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
